The Skinny on MASLD: From Nomenclature to Novel Therapies
OverviewJoin us for this activity that provides clinicians with a practical framework for metabolic dysfunction-associated steatotic liver disease (MASLD). It reviews the updated nomenclature and diagnostic criteria, a stepwise noninvasive risk-stratification pathway (FIB-4, VCTE, MRE, ELF), the multidisciplinary care model, and the appropriate selection, monitoring, and response assessment of newly approved MASH pharmacotherapies (resmetirom and semaglutide).
RegistrationRegistration for all practitioners - free.
To register for this activity, please click HERE
CreditsAMA PRA Category 1 Credits™ (1.00 hours), AAPA Category 1 CME credits (1.00 hours), ANCC Contact Hours (1.00 hours), Non-Physician Participation Credit (1.00 hours)
Target AudienceSpecialties - Family Medicine & Community Health, Gastroenterology & Hepatology, Internal MedicineProfessions - Advance Practice Nurse (APN), Non-Physician, Nurse, Physician, Physician Associate, Registered Nurse (RN) ObjectivesAt the conclusion of this activity, learners should be able to:
1. Apply the 2023 MASLD nomenclature and diagnostic criteria - hepatic steatosis on imaging plus at least one cardiometabolic risk factor - and the alcohol thresholds used to exclude primary alcohol-related liver disease.
2. Perform primary risk stratification with FIB-4 in the primary care setting and determine appropriate reassessment intervals or referral based on low, intermediate, and high-risk results.
3. Interpret secondary noninvasive tests (VCTE, MRE, ELF) to identify clinically significant fibrosis, recognize suspected cirrhosis, and identify when liver biopsy remains appropriate.
4. Select appropriate candidates for MASH pharmacotherapy with resmetirom or semaglutide, applying eligibility criteria, contraindications, and the universal mandates of cardiometabolic risk reduction, alcohol monitoring, and lifestyle management.
5. Implement the recommended safety-monitoring cadence and evaluate treatment response at 12 months (resmetirom) and 72 weeks (semaglutide) to continue, re-evaluate, or discontinue therapy.
AccreditationIn support of improving patient care, Stanford Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation
American Medical Association (AMA)
Stanford Medicine designates this Live Activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
American Nurses Credentialing Center (ANCC)
Stanford Medicine designates this Live Activity for a maximum of 1.00 ANCC contact hours.
American Academy of Physician Associates (AAPA) - Live
Stanford Medicine has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This live activity is designated for 1.00 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.